Dr. Mathai Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.
Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.
Prior to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products, two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).
Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his medical degree. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University's Department of Chemistry, working with George Whitesides. He received his Bachelors of Science in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.